Medidata Solutions Selected by Progenics Pharmaceuticals for Integration of EDC and IVRS
Medidata Solutions today announced that Progenics Pharmaceuticals, Inc. has selected the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform. Progenics has decided to implement Rave integrated with United BioSource Corp’s (UBC) interactive voice response system (IVRS) to manage a Phase III study evaluating methylnaltrexone, an opioid-induced constipation treatment, throughout investigative sites in Europe, Canada and the U.S.
Based in Tarrytown, NY, Progenics focuses on innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases, with principal programs directed toward supportive care, oncology and infectious diseases.
To implement the integration process, UBC also provided a unified project management system for multi-technology implementation and integration. UBC has strategically partnered with Medidata for a number of years, joining the Medidata ASPire to Win® partner program for contract research organizations in 2007 and becoming a Medidata Technology Partner for its IVRS integration with Rave in 2009.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
